P84.06 Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study.

Details

Language :

English

ISSN :

15560864

Volume :

16

Issue :

3

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

149366860

Full Text :

https://doi.org/10.1016/j.jtho.2021.01.1205